Jazz Pharmaceuticals plc completed the divestiture of Sunosi (solriamfetol) in the United States. to Axsome Therapeutics Inc.

Jazz Pharmaceuticals Plc’s treatment for a form of sleep disorder was recommended for approval by a panel of the European Medicines Agency (EMA).

Harmony Biosciences snagged approval from the U.S. FDA for the company’s first commercial product, a treatment for narcolepsy.